SLRX - Salarius Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.0000
-0.3100 (-7.19%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.3100
Open3.9632
Bid2.8300 x 3000
Ask11.0000 x 800
Day's Range3.9500 - 4.1400
52 Week Range2.9100 - 24.4500
Volume24,874
Avg. Volume26,725
Market Cap16.274M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.1360
Earnings DateMar 4, 2020 - Mar 9, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
  • GlobeNewswire

    Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

    HOUSTON, Nov. 13, 2019 -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its.

  • Houston pharma co. lands nearly $11M investment from Chicago group
    American City Business Journals

    Houston pharma co. lands nearly $11M investment from Chicago group

    Because of the investment, the Houston pharmaceutical company has additional capital to advance its cancer drug through clinical trials.

  • GlobeNewswire

    Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it has entered into a $10.9 million common stock purchase agreement, including a $1.0 million initial common stock purchase, with Aspire Capital Fund, LLC, a Chicago-based institutional investor. With the investment by Aspire plus non-dilutive funding from the Cancer Prevention Research Institute of Texas (CPRIT) and ongoing financial support from the National Pediatric Cancer Foundation, Salarius believes it is well-capitalized to advance its current clinical programs through a number of near-term, value creating milestones, including early safety and efficacy data readouts from the ongoing Phase 1/2 clinical trial of Seclidemstat, Salarius’ lead drug candidate, in Ewing sarcoma and the Phase 1 clinical trial of Seclidemstat in advanced solid tumors.

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference Lineup October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • GlobeNewswire

    Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its participation at two upcoming investor conferences. On October 17, 2019, management will participate in a panel at the Oppenheimer Oncology Summit in Houston, TX. Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most.

  • GlobeNewswire

    Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Nationwide Children’s Hospital (Nationwide Children’s) in Columbus, OH have been added as clinical trial sites in the ongoing Phase 1/2 clinical trial of Seclidemstat for the treatment of Ewing sarcoma.  The addition of MSKCC and Nationwide Children’s brings the total number of active clinical trial sites to eight.

  • GlobeNewswire

    Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials

    The Phase 1/2 clinical trial of Seclidemstat in Ewing sarcoma and Phase 1 AST clinical trial are designed as open-label dose-finding studies to determine the maximum tolerated dose (MTD) and initial safety profile of Seclidemstat.  Seclidemstat is administered daily as an oral tablet, with each cohort receiving an increased dose of study medication. This MTD, as determined by the Safety Review Committee, will then be used to treat a larger group of patients to confirm the safety profile for Seclidemstat and capture additional information regarding pharmacokinetics and potential preliminary efficacy.

  • GlobeNewswire

    Salarius Pharmaceuticals Announces Senior Leadership Changes

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment of Scott Jordan to the new role of Chief Business Officer and the appointment of Mark Rosenblum to the position of Executive Vice President Finance and Interim Chief Financial Officer.

  • GlobeNewswire

    Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for Childhood Cancer Awareness Month, designated as the month of September. Recognizing the work underway by the National Pediatric Cancer Foundation and the many other organizations, foundations and associations around the world to raise awareness of childhood cancers, Salarius joins with these groups in exploring targeted treatments for children and their families seeking new therapeutic options. According to data from the U.S. Centers for Disease Control and Prevention, approximately 15,000 U.S. children and adolescents younger than 20 years will receive a cancer diagnosis each year.  In the past 40 years, less than 10 drugs have been developed for use in children with cancer, a number that pales in comparison to the hundreds developed for adult cancers.  Despite improvements in overall survival rates, survival rates for some types of childhood cancer remain discouragingly low, and some childhood and adolescent cancer survivors often face long-term complications, including heart disease, infertility or secondary cancers related to their treatment.

  • GlobeNewswire

    Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma

    The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat, for the treatment of glioblastoma. It is currently being tested by Salarius in a Phase 1 study for refractory or relapsed Ewing’s sarcoma and a Phase 1 study for Advanced Solid Tumors. Seclidemstat is among the most clinically advanced reversible LSD1 inhibitors in development, and its potential effect on glioblastoma represents a promising new therapeutic treatment option.

  • GlobeNewswire

    Salarius Pharmaceuticals CEO Issues Letter to Stockholders

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that its chief executive officer, David Arthur, issued an open letter to Salarius’ stockholders following the completion of the reverse merger with Flex Pharma, Inc. The following letter can also be viewed on Salarius’ website. Following the reverse merger, Salarius’ stockholder base is now comprised of a combination of former Flex Pharma stockholders, former unit holders of Salarius Pharmaceuticals, LLC, and new stockholders. The purpose of this letter is to provide each of you with an overview and update on Salarius Pharmaceuticals, Inc. and our plan for building stockholder value by advancing clinical programs.

  • Can We See Significant Insider Ownership On The Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Share Register?
    Simply Wall St.

    Can We See Significant Insider Ownership On The Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Share Register?

    A look at the shareholders of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) can tell us which group is most powerful...

  • GlobeNewswire

    Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that President and Chief Executive Officer David Arthur and other members of the management team, will ring the Nasdaq Opening Bell on Tuesday, July 30, 2019. The Opening Bell ceremony will be broadcast live starting at 9:15am Eastern Time from the Nasdaq MarketSite Tower in New York City. David Arthur, President and CEO of Salarius Pharmaceuticals, stated, “This is a great day for Salarius, and it is our honor to ring the Nasdaq Opening Bell commemorating our recent public listing.

  • GlobeNewswire

    Salarius Pharmaceuticals Successfully Monetizes Legacy Consumer Product

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it completed the sale of HOTSHOT, a novel consumer beverage formerly marketed by Flex Innovation Group LLC, a subsidiary of Salarius Pharmaceuticals, Inc. (f/k/a Flex Pharma, Inc.), pursuant to an asset purchase agreement with Cliff-Cartwright Corporation. HOTSHOT is used by endurance athletes who drink it before, during, and after exercise to prevent and treat Exercise Associated Muscles Cramps (EAMCs). Prior to completing the merger with then privately-held Salarius Pharmaceuticals LLC, Flex Pharma announced its intent to sell its consumer division as part of a broader effort to seek strategic alternatives to enhance stockholder value, including the potential sale of certain assets of Flex Innovation Group LLC.

  • GlobeNewswire

    Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it has enrolled the first patient in a Phase 1 clinical study of the company’s lead compound, Seclidemstat, in patients with advanced solid tumors resistant to standard-of-care therapies. This is Salarius’ second Phase 1 clinical study for Seclidemstat, which is also the subject of an ongoing clinical study focused on Ewing sarcoma, a devastating bone and soft tissue cancer for which Seclidemstat has Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA).

  • GlobeNewswire

    Salarius Pharmaceuticals Announces Closing of Strategic Merger with Flex Pharma

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius Pharmaceuticals, LLC, has closed its merger with Flex Pharma, Inc.’s wholly owned subsidiary on July 19, 2019. Flex Pharma, Inc. has been renamed and will operate as Salarius Pharmaceuticals, Inc. The newly combined company will focus on the continued development of Salarius’ clinical pipeline, which targets rare, orphan cancers for which no approved targeted treatments are currently available and cancers with a high unmet need. The company will be led by Salarius’ current management team under the leadership of President and CEO, David Arthur.